Viridian Therapeutics Files 8-K on Financial Condition
Ticker: VRDN · Form: 8-K · Filed: Feb 27, 2024 · CIK: 1590750
Sentiment: neutral
Topics: 8-K filing, financial reporting, corporate governance
TL;DR
**Viridian Therapeutics just filed an 8-K on their financials, but the actual numbers aren't in this snippet!**
AI Summary
Viridian Therapeutics, Inc. (CIK: 0001590750) filed an 8-K on February 27, 2024, reporting on its results of operations and financial condition, as well as financial statements and exhibits. The filing indicates the earliest event reported also occurred on February 27, 2024. Specific financial details or outcomes are not provided in this excerpt of the filing.
Why It Matters
This filing ensures regulatory transparency regarding Viridian Therapeutics' financial status and operations, providing public access to information that could influence investor decisions.
Risk Assessment
Risk Level: low — This excerpt is merely a notification of an 8-K filing regarding financial condition, without disclosing any specific positive or negative financial results, thus posing low immediate risk based on the provided text.
Key Players & Entities
- Viridian Therapeutics, Inc. (company) — registrant
- February 27, 2024 (date) — date of earliest event reported
- Delaware (company) — state of incorporation
- 001-36483 (other) — Commission File Number
- 47-1187261 (other) — IRS Employer Identification Number
- Waltham, MA (other) — business address city and state
- MIRAGEN THERAPEUTICS, INC. (company) — former company name
- SIGNAL GENETICS, INC. (company) — former company name
FAQ
What is the full legal name of the registrant filing this 8-K?
The full legal name of the registrant is Viridian Therapeutics, Inc.
What was the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported was February 27, 2024.
In which state is Viridian Therapeutics, Inc. incorporated?
Viridian Therapeutics, Inc. is incorporated in Delaware.
What specific items of information are reported in this 8-K, according to the filing?
The 8-K reports on 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits'.
What was one of the former names of Viridian Therapeutics, Inc.?
One of the former names of Viridian Therapeutics, Inc. was MIRAGEN THERAPEUTICS, INC.
Filing Stats: 615 words · 2 min read · ~2 pages · Grade level 12.7 · Accepted 2024-02-27 16:07:35
Key Financial Figures
- $0.01 — nge on which registered Common Stock, $0.01 par value VRDN The Nasdaq Stock Mar
- $645.7 million — press release that it had approximately $645.7 million of cash, cash equivalents and short-ter
Filing Documents
- d802648d8k.htm (8-K) — 26KB
- d802648dex991.htm (EX-99.1) — 75KB
- g802648g0227081338081.jpg (GRAPHIC) — 2KB
- g802648g0227105128467.jpg (GRAPHIC) — 3KB
- 0001193125-24-047916.txt ( ) — 243KB
- vrdn-20240227.xsd (EX-101.SCH) — 3KB
- vrdn-20240227_lab.xml (EX-101.LAB) — 18KB
- vrdn-20240227_pre.xml (EX-101.PRE) — 11KB
- d802648d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits . Exhibit Number Exhibit Description 99.1 Press release, dated February 27, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Viridian Therapeutics, Inc. Date: February 27, 2024 By: /s/ Stephen Mahoney Stephen Mahoney President, Chief Executive Officer, and Director